One year follow-up of hyperuricaemic hypertensive patients treated with tienilic acid or a diuretic with or without uric acid-lowering drugs.
D000469:Alkaline Phosphatase / Q000097:blood; D000584:Amiloride / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003518:Cyclopenthiazide / Q000627:therapeutic use*; D004232:Diuretics; D005260:Female; D005500:Follow-Up Studies; D006016:Glycolates / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*; D013989:Ticrynafen / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*
D004232:Diuretics; D006016:Glycolates; D011412:Propanolamines; D011719:Pyrazines; D049993:Sodium Chloride Symporter Inhibitors; D014527:Uric Acid; D000584:Amiloride; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D008790:Metoprolol; D013989:Ticrynafen; D001663:Bilirubin; D003518:Cyclopenthiazide